Body mass index is inversely associated with osteoblastic activity in patients undergoing hemodialysis
- Theodoros Eleftheriadis
- Georgia Antoniadi
- Georgios Pissas
- Evdokia Nikolaou
- Ioannis Stefanidis
Affiliations: Department of Nephrology, Faculty of Medicine, University of Thessaly, 41110 Larissa, Greece, Hemodialysis Unit, General Hospital of Serres, 62100 Serres, Greece
- Published online on: October 10, 2023 https://doi.org/10.3892/wasj.2023.205
Copyright : © Eleftheriadis
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License [CC BY 4.0].
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Triggered by the association of malnutrition with the incidence of fractures in patients undergoing hemodialysis (HD), the present study evaluated whether the body mass index (BMI) is associated with serum markers of osteoblastic or osteoclastic activity in this population. The levels of the osteoblastic markers, total procollagen type‑1 aminoterminal propeptide (P1NP) and osteocalcin (OC), the osteoclastic marker, β‑isomerized C‑terminal cross‑linked peptide of collagen type I (β‑CTx), and those of the intact parathyroid hormone (iPTH) were measured in the serum of 59 patients undergoing HD. iPTH, P1NP, OC and β‑CTx were intercorrelated. BMI inversely correlated with the osteoblastic markers, P1NP and OC, but not with the osteoclastic marker, β‑CTx. Age negatively correlated with OC, β‑CTx and iPTH. The levels of P1NP, OC and β‑CTx were lower in patients with diabetes mellitus. BMI affected the osteoblastic markers independently of age, diabetes mellitus and iPTH. Thus, BMI inversely correlates with markers of osteoblastic activity in patients undergoing HD. However, other studies are required to confirm causality in this correlation. If confirmed, then enhancing osteoblastic activity by improving the nutritional status may become another therapeutic strategy against chronic kidney disease‑mineral bone disease.